Loading
Life sciences · Journal article
Advanced Science · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic investigation proposing that tamoxifen induces both immunogenic (STING-mediated) and immunosuppressive (CEACAM1-driven) effects in the tumor microenvironment, and that anti-TIM3 therapy may counteract the latter. The work is exploratory and raises a hypothesis about combination therapy rather than demonstrating clinical efficacy.
Journal article. Breast cancer (ER-positive and ER-negative tumors).
Tamoxifen induces mitochondrial DNA damage and disrupts RACK7/KDM5C complex, resulting in STING accumulation and type I interferon pathway activation Tamoxifen elevates CEACAM1 expression via RACK7/KDM5C axis, driving T-cell exhaustion Anti-TIM3 immunotherapy combined with tamoxifen mitigates tamoxifen's immunosuppressive effects
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The proposed combination of anti-TIM3 therapy with tamoxifen is suggested as potentially beneficial, but this remains a mechanistic hypothesis unsupported by clinical trial data. Clinicians should not change practice based on this work.
Mechanistic study proposing a dual-role model of tamoxifen in shaping the tumor microenvironment and suggesting a combination strategy; lacks clinical efficacy data and appears exploratory in nature.
The proposed combination of anti-TIM3 therapy with tamoxifen is suggested as potentially beneficial, but this remains a mechanistic hypothesis unsupported by clinical trial data. Clinicians should not change practice based on this work.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Despite advancements in immune checkpoint blockade (ICB) therapy, breast cancer shows limited response to anti-PD1/PD-L1 treatments, emphasizing the need for alternative ICB targets. Here, we reveal that endocrine therapeutics, specifically tamoxifen, create an immunosuppressive yet primed tumor microenvironment conducive to anti-TIM3 immunotherapy. Tamoxifen induces mitochondrial DNA damage and disrupts the RACK7/KDM5C histone demethylase complex, resulting in STING accumulation and activation of the type I interferon (IFN-I) pathway, thereby fostering an immunogenic tumor microenvironment. However, tamoxifen also elevates CEACAM1 expression via a RACK7/KDM5C axis, driving T-cell exhaustion and limiting tumor elimination. This dual effect of tamoxifen - promoting STING-mediated immunogenicity while upregulating CEACAM1 expression - shapes the tumor-immune microenvironment in both ER-positive and ER-negative tumors. Notably, combining anti-TIM3 immunotherapy with tamoxifen mitigates its immunosuppressive effects, potentially enhancing ICB efficacy. Our findings highlight the therapeutic potential of integrating anti-TIM3 immunotherapy with endocrine therapy to improve outcomes for breast cancer patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.